Pruritus mediator in skin

"Pruritus mediators in skin" is not a single molecular target but rather a collective term referring to the diverse group of molecules that induce or modulate itching sensations within the skin. These include classical mediators such as **histamine**—released primarily from mast cells and acting via H1 and H4 receptors—as well as numerous non-histaminergic factors like **interleukin 31**, **periostin**, **thymic stromal lymphopoietin (TSLP)**, prostaglandins, leukotrienes, acetylcholine, proteases activating PAR2 receptors, neuropeptides such as substance P and nerve growth factor. These mediators are produced by various cell types including keratinocytes, fibroblasts, mast cells, basophils, eosinophils, dendritic cells and macrophages. They act through different molecular pathways involving G protein-coupled receptors (H1R/H4R), cytokine receptors (IL31RA/OSMR), integrins (αVβ3 for periostin), ion channels and others. The role of these mediators varies by disease context; for example, histamine is central in urticaria but less so in chronic conditions like atopic dermatitis or prurigo nodularis where IL‑31 and periostin play more prominent roles. Targeting individual pruritogens has led to new therapies such as anti‑IL‑31 antibodies for severe itch disorders. However, the broad diversity among these molecules means "pruritus mediator" is not itself a druggable target but rather an umbrella concept encompassing multiple distinct therapeutic targets.[1][2][3][4]

Other names

PruritogensItch mediatorsSkin pruritogensPruritus-inducing molecules

Blockade of histamine receptors to reduce itch signaling[2]; Neutralization of interleukin 31 to decrease pruritus[2]; Inhibition of protease activity at PAR2 to reduce non-histaminergic itch[3]